A Cross-Reactive Mouse Monoclonal Antibody against Rhinovirus Mediates Phagocytosis In Vitro

Human rhinoviruses (RVs) are the main cause of the common cold worldwide. To date, more than 160 serotypes of the virus have been recognized. These viruses are categorized into three major groups: A, B, and C. There are currently no approved vaccines available to prevent infection with RVs. We desig...

Full description

Bibliographic Details
Main Authors: Mohammad Amin Behzadi, James Duehr, Angela Choi, Michael Schotsaert, Adolfo García-Sastre, Peter Palese, Raffael Nachbagauer
Format: Article
Language:English
Published: MDPI AG 2020-07-01
Series:Proceedings
Subjects:
Online Access:https://www.mdpi.com/2504-3900/50/1/132
_version_ 1797562491140571136
author Mohammad Amin Behzadi
James Duehr
Angela Choi
Michael Schotsaert
Adolfo García-Sastre
Peter Palese
Raffael Nachbagauer
author_facet Mohammad Amin Behzadi
James Duehr
Angela Choi
Michael Schotsaert
Adolfo García-Sastre
Peter Palese
Raffael Nachbagauer
author_sort Mohammad Amin Behzadi
collection DOAJ
description Human rhinoviruses (RVs) are the main cause of the common cold worldwide. To date, more than 160 serotypes of the virus have been recognized. These viruses are categorized into three major groups: A, B, and C. There are currently no approved vaccines available to prevent infection with RVs. We designed a mouse immunization strategy that aimed to elicit a humoral response against conserved regions of capsid proteins of RV-A viruses. To this end, recombinant DNA plasmids expressing the capsid proteins (VP1-4) and two proteases (2A and 3C) of RV1A, 16, 49, 68, and 71 were engineered. Mice were sequentially vaccinated with these DNA plasmids at three-week intervals. After a final boost with purified whole virus using the RV15 strain, mice spleens were extracted and cells expressing monoclonal antibodies (mAbs) were generated by hybridoma fusion. A total of 98 mAbs with reactivity to different strains of RV-A were isolated. After isotyping, 22 mAbs expressing an IgG Fc-domain were selected for further expansion and purification. Three mAbs showed cross-reactivity against multiple strains of RV-A viruses by ELISA, including 1A, 1B, 15, 16, and 49. Additional mAbs had strain-specific binding patterns, with a surprising number of mAbs showing reactivity to RV15, the strain used for the final vaccination. Using a microneutralization assay, we found that the RV15-specific mAbs, but not the cross-reactive mAbs, were highly neutralizing. Additional testing in a flow cytometry-based antibody-dependent cellular phagocytosis (ADCP) assay revealed a high degree of ADCP activity for one of the cross-reactive mAbs. Epitope mapping of the neutralizing mAbs via escape mutant viruses revealed binding sites with a shared epitope on VP1 of RV15. The epitope of the ADCP-active, non-neutralizing mAb was determined by the microarray analysis of cyclic constrained peptides generated from the VP1 capsid protein. This study identified a cross-reactive mAb that mediates phagocytosis. These findings could be used toward the development of vaccines against RV. The full study results have since been published (https://doi.org/10.1038/s41598-020-66600-x).
first_indexed 2024-03-10T18:28:56Z
format Article
id doaj.art-a92569adb00c4e1c9268bf501cfa6065
institution Directory Open Access Journal
issn 2504-3900
language English
last_indexed 2024-03-10T18:28:56Z
publishDate 2020-07-01
publisher MDPI AG
record_format Article
series Proceedings
spelling doaj.art-a92569adb00c4e1c9268bf501cfa60652023-11-20T06:47:35ZengMDPI AGProceedings2504-39002020-07-0150113210.3390/proceedings2020050132A Cross-Reactive Mouse Monoclonal Antibody against Rhinovirus Mediates Phagocytosis In VitroMohammad Amin Behzadi0James Duehr1Angela Choi2Michael Schotsaert3Adolfo García-Sastre4Peter Palese5Raffael Nachbagauer6Department of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USADepartment of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USADepartment of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USADepartment of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USADepartment of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USADepartment of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USADepartment of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USAHuman rhinoviruses (RVs) are the main cause of the common cold worldwide. To date, more than 160 serotypes of the virus have been recognized. These viruses are categorized into three major groups: A, B, and C. There are currently no approved vaccines available to prevent infection with RVs. We designed a mouse immunization strategy that aimed to elicit a humoral response against conserved regions of capsid proteins of RV-A viruses. To this end, recombinant DNA plasmids expressing the capsid proteins (VP1-4) and two proteases (2A and 3C) of RV1A, 16, 49, 68, and 71 were engineered. Mice were sequentially vaccinated with these DNA plasmids at three-week intervals. After a final boost with purified whole virus using the RV15 strain, mice spleens were extracted and cells expressing monoclonal antibodies (mAbs) were generated by hybridoma fusion. A total of 98 mAbs with reactivity to different strains of RV-A were isolated. After isotyping, 22 mAbs expressing an IgG Fc-domain were selected for further expansion and purification. Three mAbs showed cross-reactivity against multiple strains of RV-A viruses by ELISA, including 1A, 1B, 15, 16, and 49. Additional mAbs had strain-specific binding patterns, with a surprising number of mAbs showing reactivity to RV15, the strain used for the final vaccination. Using a microneutralization assay, we found that the RV15-specific mAbs, but not the cross-reactive mAbs, were highly neutralizing. Additional testing in a flow cytometry-based antibody-dependent cellular phagocytosis (ADCP) assay revealed a high degree of ADCP activity for one of the cross-reactive mAbs. Epitope mapping of the neutralizing mAbs via escape mutant viruses revealed binding sites with a shared epitope on VP1 of RV15. The epitope of the ADCP-active, non-neutralizing mAb was determined by the microarray analysis of cyclic constrained peptides generated from the VP1 capsid protein. This study identified a cross-reactive mAb that mediates phagocytosis. These findings could be used toward the development of vaccines against RV. The full study results have since been published (https://doi.org/10.1038/s41598-020-66600-x).https://www.mdpi.com/2504-3900/50/1/132rhinovirusmonoclonal antibodyphagocytosisneutralizationcross-reactive
spellingShingle Mohammad Amin Behzadi
James Duehr
Angela Choi
Michael Schotsaert
Adolfo García-Sastre
Peter Palese
Raffael Nachbagauer
A Cross-Reactive Mouse Monoclonal Antibody against Rhinovirus Mediates Phagocytosis In Vitro
Proceedings
rhinovirus
monoclonal antibody
phagocytosis
neutralization
cross-reactive
title A Cross-Reactive Mouse Monoclonal Antibody against Rhinovirus Mediates Phagocytosis In Vitro
title_full A Cross-Reactive Mouse Monoclonal Antibody against Rhinovirus Mediates Phagocytosis In Vitro
title_fullStr A Cross-Reactive Mouse Monoclonal Antibody against Rhinovirus Mediates Phagocytosis In Vitro
title_full_unstemmed A Cross-Reactive Mouse Monoclonal Antibody against Rhinovirus Mediates Phagocytosis In Vitro
title_short A Cross-Reactive Mouse Monoclonal Antibody against Rhinovirus Mediates Phagocytosis In Vitro
title_sort cross reactive mouse monoclonal antibody against rhinovirus mediates phagocytosis in vitro
topic rhinovirus
monoclonal antibody
phagocytosis
neutralization
cross-reactive
url https://www.mdpi.com/2504-3900/50/1/132
work_keys_str_mv AT mohammadaminbehzadi acrossreactivemousemonoclonalantibodyagainstrhinovirusmediatesphagocytosisinvitro
AT jamesduehr acrossreactivemousemonoclonalantibodyagainstrhinovirusmediatesphagocytosisinvitro
AT angelachoi acrossreactivemousemonoclonalantibodyagainstrhinovirusmediatesphagocytosisinvitro
AT michaelschotsaert acrossreactivemousemonoclonalantibodyagainstrhinovirusmediatesphagocytosisinvitro
AT adolfogarciasastre acrossreactivemousemonoclonalantibodyagainstrhinovirusmediatesphagocytosisinvitro
AT peterpalese acrossreactivemousemonoclonalantibodyagainstrhinovirusmediatesphagocytosisinvitro
AT raffaelnachbagauer acrossreactivemousemonoclonalantibodyagainstrhinovirusmediatesphagocytosisinvitro
AT mohammadaminbehzadi crossreactivemousemonoclonalantibodyagainstrhinovirusmediatesphagocytosisinvitro
AT jamesduehr crossreactivemousemonoclonalantibodyagainstrhinovirusmediatesphagocytosisinvitro
AT angelachoi crossreactivemousemonoclonalantibodyagainstrhinovirusmediatesphagocytosisinvitro
AT michaelschotsaert crossreactivemousemonoclonalantibodyagainstrhinovirusmediatesphagocytosisinvitro
AT adolfogarciasastre crossreactivemousemonoclonalantibodyagainstrhinovirusmediatesphagocytosisinvitro
AT peterpalese crossreactivemousemonoclonalantibodyagainstrhinovirusmediatesphagocytosisinvitro
AT raffaelnachbagauer crossreactivemousemonoclonalantibodyagainstrhinovirusmediatesphagocytosisinvitro